363 related articles for article (PubMed ID: 23553425)
1. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.
Lu D; Joshi A; Wang B; Olsen S; Yi JH; Krop IE; Burris HA; Girish S
Clin Pharmacokinet; 2013 Aug; 52(8):657-72. PubMed ID: 23553425
[TBL] [Abstract][Full Text] [Related]
2. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.
Lu D; Girish S; Gao Y; Wang B; Yi JH; Guardino E; Samant M; Cobleigh M; Rimawi M; Conte P; Jin JY
Cancer Chemother Pharmacol; 2014 Aug; 74(2):399-410. PubMed ID: 24939213
[TBL] [Abstract][Full Text] [Related]
4. Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
Li C; Wang B; Lu D; Jin JY; Gao Y; Matsunaga K; Igawa Y; Nijem I; Lu M; Strasak A; Chernyukhin N; Girish S
Cancer Chemother Pharmacol; 2016 Sep; 78(3):547-58. PubMed ID: 27423671
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.
Yamamoto H; Ando M; Aogi K; Iwata H; Tamura K; Yonemori K; Shimizu C; Hara F; Takabatake D; Hattori M; Asakawa T; Fujiwara Y
Jpn J Clin Oncol; 2015 Jan; 45(1):12-8. PubMed ID: 25332421
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.
Girish S; Gupta M; Wang B; Lu D; Krop IE; Vogel CL; Burris Iii HA; LoRusso PM; Yi JH; Saad O; Tong B; Chu YW; Holden S; Joshi A
Cancer Chemother Pharmacol; 2012 May; 69(5):1229-40. PubMed ID: 22271209
[TBL] [Abstract][Full Text] [Related]
7. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer.
Chudasama VL; Schaedeli Stark F; Harrold JM; Tibbitts J; Girish SR; Gupta M; Frey N; Mager DE
Clin Pharmacol Ther; 2012 Oct; 92(4):520-7. PubMed ID: 22968044
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
[TBL] [Abstract][Full Text] [Related]
10. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates.
Erickson HK; Lewis Phillips GD; Leipold DD; Provenzano CA; Mai E; Johnson HA; Gunter B; Audette CA; Gupta M; Pinkas J; Tibbitts J
Mol Cancer Ther; 2012 May; 11(5):1133-42. PubMed ID: 22408268
[TBL] [Abstract][Full Text] [Related]
11. Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer.
Lambert JM; Chari RV
J Med Chem; 2014 Aug; 57(16):6949-64. PubMed ID: 24967516
[TBL] [Abstract][Full Text] [Related]
12. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.
Boyraz B; Sendur MA; Aksoy S; Babacan T; Roach EC; Kizilarslanoglu MC; Petekkaya I; Altundag K
Curr Med Res Opin; 2013 Apr; 29(4):405-14. PubMed ID: 23402224
[TBL] [Abstract][Full Text] [Related]
14. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).
Singh AP; Maass KF; Betts AM; Wittrup KD; Kulkarni C; King LE; Khot A; Shah DK
AAPS J; 2016 Jul; 18(4):861-75. PubMed ID: 27029797
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
Krop I; Winer EP
Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
[TBL] [Abstract][Full Text] [Related]
16. A multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.
Kashiwaba M; Ito Y; Takao S; Doihara H; Rai Y; Kanatani K; Takashima S; Masuda N
Jpn J Clin Oncol; 2016 May; 46(5):407-14. PubMed ID: 26917603
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Gupta M; Lorusso PM; Wang B; Yi JH; Burris HA; Beeram M; Modi S; Chu YW; Agresta S; Klencke B; Joshi A; Girish S
J Clin Pharmacol; 2012 May; 52(5):691-703. PubMed ID: 21953571
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
LoRusso PM; Weiss D; Guardino E; Girish S; Sliwkowski MX
Clin Cancer Res; 2011 Oct; 17(20):6437-47. PubMed ID: 22003071
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Chen SC; Kagedal M; Gao Y; Wang B; Harle-Yge ML; Girish S; Jin J; Li C
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1147-1159. PubMed ID: 29043411
[TBL] [Abstract][Full Text] [Related]
20. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.
Martínez MT; Pérez-Fidalgo JA; Martín-Martorell P; Cejalvo JM; Pons V; Bermejo B; Martín M; Albanell J; Lluch A
Crit Rev Oncol Hematol; 2016 Jan; 97():96-106. PubMed ID: 26318092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
